SeaStar Medical will present at the HC Wainwright Global Investment Conference on September 5, 2025, discussing its therapies for organ failure.
Quiver AI Summary
SeaStar Medical Holding Corporation, focused on transforming treatments for critically ill patients, announced its participation in the HC Wainwright 27th Annual Global Investment Conference, where their presentation can be viewed on September 5, 2025. The company’s first commercial product, QUELIMMUNE, which utilizes its patented Selective Cytopheretic Device (SCD) technology, was approved by the FDA in 2024 for treating life-threatening acute kidney injury in critically ill pediatric patients. SeaStar has received Breakthrough Device Designation from the FDA for six therapeutic indications and is currently conducting a pivotal trial of its SCD therapy in adult patients with acute kidney injury. For more details, interested parties can visit the SeaStar Medical website.
Potential Positives
- Participation in the HC Wainwright 27th Annual Global Investment Conference enhances company visibility and credibility in the healthcare investment community.
- The QUELIMMUNE therapy, as the only FDA-approved product for a rare and life-threatening condition, positions SeaStar Medical as a leader in treating acute kidney injury (AKI) in pediatric patients.
- The Breakthrough Device Designation awarded for six therapeutic indications indicates significant potential for accelerated market access and favorable clinical reimbursement strategies.
- The ongoing pivotal trial in adult patients with AKI demonstrates SeaStar Medical's commitment to expanding treatment options in a large patient population suffering from a significant unmet medical need.
Potential Negatives
- The press release lacks specific financial details or projections related to the company's participation in the investment conference, which may raise concerns about transparency and investor confidence.
- There is no mention of recent clinical trial results or updates on the pivotal trial for adult patients, leaving stakeholders uncertain about the development progress and potential risks associated with the new therapy.
- The focus on an ultra-rare condition may limit market potential and revenue opportunities, which could be viewed negatively by investors looking for broader applicability of the company's products.
FAQ
What is SeaStar Medical Holding Corporation?
SeaStar Medical Holding Corporation is a healthcare company focused on innovating treatments for critically ill patients with organ failure.
When is SeaStar Medical's presentation at the HC Wainwright Conference?
The presentation will take place on Friday, September 5, 2025, at 7:00 am Eastern Time.
How can I access SeaStar Medical's presentation?
You can access the presentation on the Events & Presentations page under Investor Relations on the SeaStar Medical website.
What is the QUELIMMUNE therapy?
QUELIMMUNE is SeaStar Medical's first FDA-approved therapy for life-threatening acute kidney injury in critically ill pediatric patients.
What is the status of SeaStar Medical's clinical trials?
SeaStar Medical is conducting a pivotal trial of its Selective Cytopheretic Device therapy in adults with acute kidney injury.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- HEEL KENNETH VAN has made 2 purchases buying 35,000 shares for an estimated $30,812 and 0 sales.
- JENNIFER A BAIRD has made 2 purchases buying 20,000 shares for an estimated $16,989 and 0 sales.
- JOHN NEUMAN purchased 40,000 shares for an estimated $14,396
- KEVIN CHUNG (Chief Medical Officer) has made 2 purchases buying 14,500 shares for an estimated $13,625 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC Wainwright 27 th Annual Global Investment Conference.
The SeaStar Medical presentation can be viewed on Friday, September 5, 2025, at 7:00 am Eastern Time. The presentation can be accessed by visiting the Events & Presentations page , located under the Investor Relations section of the SeaStar Medical website , and will be available for 60 days following the presentation.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. It was approved in 2024 by the U.S. Food and Drug Administration (FDA). QUELIMMUNE is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the US annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
[email protected]
